Comparative Pharmacology
Head-to-head clinical analysis: ACTISITE versus DEMECLOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTISITE versus DEMECLOCYCLINE HYDROCHLORIDE.
ACTISITE vs DEMECLOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
None Documented
None Documented
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic